OCGN Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Ocugen

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

4 days ago - By: Ocugen

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

25 days ago - By: Ocugen

Ocugen to Present at Industry and Investor Conferences in October 2025

25 days ago - By: Ocugen

Ocugen to Present at Industry and Investor Conferences in October 2025

a month ago - By: Benzinga

Forecasting The Future: 4 Analyst Projections For Ocugen

3 months ago - By: Benzinga

Demystifying Ocugen: Insights From 5 Analyst Reviews

3 months ago - By: The Motley Fool

Ocugen (OCGN) Q2 Revenue Jumps 20%

a month ago - By: The Motley Fool

Why Ocugen Stock Zoomed 12% Higher Today

a month ago - By: Ocugen

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

a month ago - By: Ocugen

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

2 months ago - By: Ocugen

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

2 months ago - By: Ocugen

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

2 months ago - By: Zacks Investment Research

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

3 months ago - By: Ocugen

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

3 months ago - By: Ocugen

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

3 months ago - By: Ocugen

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

3 months ago - By: Ocugen

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

3 months ago - By: Ocugen

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

3 months ago - By: Ocugen

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

3 months ago - By: Zacks Investment Research - Mentions: CCCC

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Ocugen

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

3 months ago - By: Ocugen

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

3 months ago - By: Ocugen

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

3 months ago - By: Ocugen

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

3 months ago - By: Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

3 months ago - By: Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

3 months ago - By: Ocugen

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

3 months ago - By: Ocugen

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

4 months ago - By: Brodsky & Smith LLC - Mentions: CARM GNTY GBCI MRC ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

4 months ago - By: Stocktwits - Mentions: SHPH NVS MRK LLY ...

5 Biotech Stocks with Highly Anticipated Pending Results

4 months ago - By: Ocugen

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

4 months ago - By: Ocugen - Mentions: CARM

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

OCUGEN INC (OCGN) Stock News

OCGN Latest News, Press Relases and Analysis